FoldRx Pharmaceuticals, a US-based drug developer backed by strategic investor Novartis, has made Georges Gemayel its executive chairman.
Gemayel also sits on the boards of Adolor and Pharmaceuticals Corporation after working at Altus Pharmaceuticals, Genzyme and Hoffmann-La Roche. Switzerland-based Novartis through its Venture Fund division has invested in FoldRx alongside venture capital firms Alta Partners, Fidelity Ventures, HealthCare Ventures and TPG Capital.